Evotec AG (EVTC) Achieves Milestone In Cardioxyl Collaboration
More News related to EVTC
- Evotec (EVTC) Awarded €2.5M Grant for Neuroprotection R&D
- Evotec Wins German Government Research Grant
- Evotec Third Quarter Financial Results: Growth of Business and Restructuring Impact Lead the Path to Sustainability
- Evotec to Voluntarily Delist From NASDAQ
- Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Evotec AG (Nasdaq: EVTC) achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing. This milestone has triggered a success payment from Cardioxyl Pharmaceuticals to Evotec.
Related Categories
FDAStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
